Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19814Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Agnantis, N. J. | en |
| dc.contributor.author | Zagorianakou, P. | en |
| dc.contributor.author | Kamina, S. | en |
| dc.contributor.author | Gorezi, M. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.contributor.author | Bai, M. | en |
| dc.date.accessioned | 2015-11-24T19:02:34Z | - |
| dc.date.available | 2015-11-24T19:02:34Z | - |
| dc.identifier.issn | 0392-9078 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19814 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Breast Neoplasms/drug therapy/mortality/*pathology/surgery | en |
| dc.subject | Chemotherapy, Adjuvant | en |
| dc.subject | Disease-Free Survival | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Staging | en |
| dc.subject | Predictive Value of Tests | en |
| dc.subject | Prognosis | en |
| dc.subject | Proto-Oncogene Proteins c-bcl-2/*analysis | en |
| dc.subject | Retrospective Studies | en |
| dc.subject | Survival Rate | en |
| dc.subject | Time Factors | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/11718212 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2001 | - |
| heal.abstract | The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry for the expression of bcl-2 protein and analyzed for disease outcome. One fourth (25%) of the cases were negative and 57% demonstrated near-absolute expression of the bcl-2 protein. No association was found between immunohistochemical detection of the protein with age, hormonal receptor status and tumor grading other than between bcl-2 and estrogen receptor expression (p=0.01). An impressively positive impact of near-absolute expression of bcl-2 on clinical outcome was identified. Our results provide evidence that quantitative assessment of bcl-2 expression constitutes a new approach in early breast cancer with potential clinical implications. We consider that molecular sub-staging of patients with stage II breast cancer by level of bcl-2 expression provides additional important prognostic information and prompts for investigation of its clinical significance on the issue of adjuvant systemic therapy. | en |
| heal.journalName | J Exp Clin Cancer Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
